RESUMEN
BACKGROUND: Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of bradykinin - RPPGF. METHODS AND RESULTS: These peptides are direct thrombin inhibitors prolonging the thrombin clotting time, activated partial thromboplastin time, and prothrombin time at >or=0.78, 1.6, and 1.6 microm, respectively. They competitively inhibit alpha-thrombin-induced cleavage of a chromogenic substrate at 4.4-8.2 microm. They do not significantly inhibit plasma kallikrein, factor (F) XIIa, FXIa, FIXa, FVIIa-TF, FXa, plasmin or cathepsin G. One form, FM19 [rOicPaF(p-Me)], blocks alpha-thrombin-induced calcium flux in fibroblasts with an IC(50) of 6.9 +/- 1.2 microm. FM19 achieved 100% inhibition of threshold alpha- or gamma-thrombin-induced platelet aggregation at 8.4 +/- 4.7 microm and 16 +/- 4 microm, respectively. The crystal structure of thrombin in complex with FM19 shows that the N-terminal D-Arg retrobinds into the S1 pocket, its second residue Oic interacts with His-57, Tyr-60a and Trp-60d, and its C-terminal p-methyl Phe engages thrombin's aryl binding site composed of Ile-174, Trp-215, and Leu-99. When administered intraperitoneal, intraduodenal, or orally to mice, FM19 prolongs thrombin clotting times and delays carotid artery thrombosis. CONCLUSION: FM19, a low affinity reversible direct thrombin inhibitor, might be useful as an add-on agent to address an unmet need in platelet inhibition in acute coronary syndromes in diabetics and others who with all current antiplatelet therapy still have reactive platelets.
Asunto(s)
Bradiquinina/química , Bradiquinina/farmacología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/farmacología , Trombina/antagonistas & inhibidores , Animales , Sitios de Unión , Bradiquinina/administración & dosificación , Trombosis de las Arterias Carótidas/tratamiento farmacológico , Cristalografía por Rayos X , Ratones , Estructura Molecular , Fragmentos de Péptidos/administración & dosificación , Agregación Plaquetaria/efectos de los fármacos , Unión Proteica , Trombina/química , Trombina/metabolismo , Tiempo de TrombinaRESUMEN
INTRODUCTION: Tedisamil is an experimental bradycardic agent possessing action potential-prolonging effects. It has been proven effective in terminating ventricular arrhythmias in several animal models and atrial flutter in a conscious dog model. There are no reports to date evaluating tedisamil's efficacy in terminating atrial fibrillation (AF). METHODS AND RESULTS: Two different canine models of AF were used. One group of dogs (n = 6) was subjected to 28 days of chronic fibrillatory pacing at 50 Hz using an implantable neural stimulator. Sustained AF was achieved in all dogs within 14 days of initiating pacing. A second set of dogs (n = 5) had AF induced via bilateral vagal stimulation. Tedisamil 1 mg/kg was 100% effective in terminating AF in both models. Cardioversion was associated with a statistically significant prolongation of the fibrillatory cycle length immediately before return to normal sinus rhythm in both models. A dose-response trial was performed in the vagal AF group as well as in a second group of three dogs that underwent chronic fibrillatory pacing. The efficacy of tedisamil was dose dependent, with limited efficacy at 0.1 and 0.3 mg/kg intravenously in both models. Tedisamil was able to prevent reinduction of sustained AF 30 minutes after administration of 1 mg/kg in the chronic pacing model in all dogs. Side effects included minor hypersalivation in most dogs receiving the 1 mg/kg dose. No ventricular ectopy or arrhythmias were observed. CONCLUSION: Tedisamil is effective for conversion of sustained AF to normal sinus rhythm in two different models of AF.
Asunto(s)
Antiarrítmicos/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico , Ciclopropanos/uso terapéutico , Animales , Antiarrítmicos/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Compuestos Bicíclicos Heterocíclicos con Puentes/administración & dosificación , Ciclopropanos/administración & dosificación , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Electrocardiografía , Frecuencia Cardíaca/efectos de los fármacos , Michigan , Modelos Cardiovasculares , Tiempo de Reacción/efectos de los fármacosRESUMEN
Intracoronary infusion of adenosine is reported to inhibit cyclic flow variations after coronary artery injury and stenosis. This study was performed in the anesthetized dog to determine if adenosine prevents arterial thrombosis and/or reocclusion after thrombolysis. Carotid and coronary arteries were instrumented with Doppler(TM) flow probes, a critical stenosis, infusion line and an anodal electrode. Two protocols were employed. In the thrombosis protocol, intracarotid infusion of adenosine (20 microg/kg/min for 3 h) did not alter cyclic flow variations or patency during induction of vessel wall injury. In the second protocol, occlusive arterial thrombi were induced by anodal current injury and lysed with local application of tissue plasminogen activator. Whereas adenosine prolonged the time to arterial occlusion, it did not affect cyclic flow variations or time to reocclusion after thrombolysis.
Asunto(s)
Adenosina/uso terapéutico , Trombosis de las Arterias Carótidas/tratamiento farmacológico , Trombosis Coronaria/tratamiento farmacológico , Terapia Trombolítica , Adenosina Difosfato/farmacología , Animales , Ácido Araquidónico/farmacología , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Arterias Carótidas/efectos de los fármacos , Arterias Carótidas/fisiopatología , Trombosis de las Arterias Carótidas/etiología , Circulación Coronaria/efectos de los fármacos , Trombosis Coronaria/etiología , Modelos Animales de Enfermedad , Perros , Traumatismos por Electricidad/complicaciones , Femenino , Fibrinolíticos/uso terapéutico , Masculino , Agregación Plaquetaria/efectos de los fármacos , Factores de Tiempo , Activador de Tejido Plasminógeno/uso terapéuticoRESUMEN
BACKGROUND: Prostanoid synthesis via the action of cyclooxygenase-2 (COX-2) is a component of the inflammatory response. Prostacyclin, a product of COX-2 in vascular endothelium, has important physiological roles, such as increasing blood flow to injured tissues, reducing leukocyte adherence, and inhibiting platelet aggregation. We examined the possibility that selective COX-2 inhibition could suppress the protective effects of prostacyclin, resulting in an alteration of the hemostatic balance and vascular tone. METHODS AND RESULTS: Circumflex coronary artery thrombosis was induced in dogs by vascular electrolytic injury. Orally administered celecoxib (COX-2 inhibition) or high-dose aspirin (HDA) (COX-1 and COX-2 inhibition) did not alter time to occlusive thrombus formation compared with controls (celecoxib 77.7+/-7.2 minutes, HDA 72.0+/-18.5 minutes, control 93.0+/-21.8 minutes). Oral HDA with an endothelial recovery period (HDA-ER) (COX-1 inhibition) produced a significant increase in time to vessel occlusion (257.0+/-41.6 minutes). The observed increase in time to occlusion was abolished when celecoxib was administered to animals dosed with HDA-ER (80.7+/-20.6 minutes). The vasomotor effect of endothelium-derived prostacyclin was examined by monitoring coronary flow during intracoronary administration of arachidonic acid or acetylcholine. In celecoxib-treated animals, vasodilation in response to arachidonic acid was reduced significantly compared with controls. CONCLUSIONS: The results indicate important physiological roles for COX-2-derived prostacyclin and raise concerns regarding an increased risk of acute vascular events in patients receiving COX-2 inhibitors. The risk may be increased in individuals with underlying inflammatory disorders, including coronary artery disease.
Asunto(s)
Trombosis Coronaria/tratamiento farmacológico , Vasos Coronarios/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/farmacología , Isoenzimas/antagonistas & inhibidores , Sistema Vasomotor/efectos de los fármacos , Acetilcolina/farmacología , Animales , Ácido Araquidónico/farmacología , Aspirina/farmacología , Benzofuranos/farmacología , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Celecoxib , Circulación Coronaria/efectos de los fármacos , Trombosis Coronaria/fisiopatología , Vasos Coronarios/fisiopatología , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa/efectos adversos , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Epoprostenol/farmacología , Agregación Plaquetaria/efectos de los fármacos , Prostaglandina-Endoperóxido Sintasas , Pirazoles , Sulfonamidas/efectos adversos , Sulfonamidas/farmacología , Tromboxano-A Sintasa/antagonistas & inhibidores , Factores de Tiempo , Vasodilatación/efectos de los fármacos , Sistema Vasomotor/fisiopatologíaRESUMEN
Acute myocardial infarct (MI) results in ischemia distal to lesions which puts heart muscle at risk for reperfusion injury (RI). Neutrophils, platelets and complement are putative mediators of RI. Recent advances in filtration technology provide integrated neutrophil and platelet removal together with complement-attenuating properties in a single blood-conditioning device. The present study characterizes the properties of a blood-conditioning filter and describes its clinical effect when used in conjunction with active hemoperfusion for acute MI. The filter reduces leukocytes by 99.9998 +/- 0.0002% (p<0.0001) and platelets by 99.9934 +/- 0.0069% (p<0.0001). Human plasma, derived from heparinized blood that was 'conditioned' by filtration, was studied using the Langendorff isolated rabbit heart preparation. The deposition of membrane attack complex and the resultant functional myocardial impairments [reflected in hemodynamic and biochemical measurements, including developed pressure, coronary blood flow, lymph-derived myocardial creatine kinase (CK)] are significantly attenuated by blood conditioning. Integration of the blood-conditioning filter into an active hemoperfusion system during primary percutaneous transluminal coronary angioplasty (PTCA) for acute MI (n=8) did not delay the procedure or cause any complications. Reperfusion of occluded coronary arteries with 300 cm3 of conditioned blood led to significant improvement in echocardiographic global wall motion scores (in standard deviations) following treatment (-1.64 +/- 0.18 to -1.45 +/- 0.15, p=0.02). Initial reperfusion of totally occluded coronary arteries with conditioned blood leads to acutely improved ventricular function. Collectively, these data provide a strong indication for continued investigation of conditioned blood reperfusion in angioplasty following acute MI for the long-term effect upon recovery of salvagable myocardium.
Asunto(s)
Angioplastia Coronaria con Balón/métodos , Infarto del Miocardio/cirugía , Reperfusión/métodos , Adulto , Anciano , Anciano de 80 o más Años , Animales , Complejo de Ataque a Membrana del Sistema Complemento/metabolismo , Complejo de Ataque a Membrana del Sistema Complemento/farmacología , Electrocardiografía , Femenino , Filtración/métodos , Humanos , Técnicas In Vitro , Leucaféresis , Masculino , Persona de Mediana Edad , Infarto del Miocardio/sangre , Infarto del Miocardio/fisiopatología , Proyectos Piloto , Plaquetoferesis , Estudios Prospectivos , Conejos , Daño por Reperfusión/etiología , Daño por Reperfusión/prevención & control , Volumen Sistólico , Función Ventricular IzquierdaRESUMEN
It is a privilege and honor to be selected by the American Society of Pharmacology and Experimental Therapeutics for the Torald Sollmann Award. I wish to take this opportunity to comment on my experiences over the last 40 plus years as both a student and a faculty member. I was trained in pharmacology as well as medicine with the goal of entering an academic career that would permit me to engage in teaching and research. The subject of my presentation focuses on the events that helped to shape my career. Attention is given to those who made it possible for me to advance in my learning, teaching, and research. In addition to having been taught by excellent instructors, I have benefitted from having many outstanding undergraduate and graduate students, as well as postdoctoral fellows, without whom much of what I feel I have accomplished would not have been possible. Being surrounded by a supportive environment and accompanied by bright and eager young students gives me reason to look toward the future with enthusiasm. I chose to take the time and space allotted to me to present a brief overview of where I have been and how many individuals played important roles in helping to achieve my goals. In essence, this composition is a tribute to my family, professional associates, and current and former students.
Asunto(s)
Farmacología/historia , Antagonistas Adrenérgicos beta/historia , Antiarrítmicos/historia , Antiarrítmicos/uso terapéutico , Distinciones y Premios , Trombosis Coronaria/historia , Trombosis Coronaria/prevención & control , Muerte Súbita Cardíaca/prevención & control , Modelos Animales de Enfermedad , Historia del Siglo XX , Humanos , Daño por Reperfusión Miocárdica/historia , Daño por Reperfusión Miocárdica/prevención & control , Farmacología/educación , Vuelo Espacial/historia , Estados UnidosRESUMEN
1. Tedisamil is a bradycardiac agent that prolongs the QT interval of the ECG and prevents cardiac arrhythmias. Given this profile, tedisamil might be expected to have proarrhythmic actions similar to Class III antiarrhythmic drugs. To address this question, the actions of dofetilide and tedisamil were examined in rabbit isolated hearts in which bradycardia was induced by AV ablation. 2. The QT interval was prolonged in a reverse rate-dependent fashion by dofetilide (3 and 30 nM) and tedisamil (0.3 and 3 microM). 3. Torsades de pointes was observed in 1/7 hearts treated with 3 nM dofetilide and 0/7 hearts treated with 0.3 microM tedisamil. The incidence of torsades de pointes was increased to 5/7 in hearts treated with 30 nM dofetilide and to 7/7 in hearts treated with 3 microM tedisamil (both P < 0.05 vs control). 4. The actions of 30 nM dofetilide and 3 microM tedisamil were also examined in hearts paced at 50, 100, 200 and 50 beats min(-1) successively. Both drugs caused torsades de pointes in 5/5 hearts paced at 50 beats min(-1); however, the incidence was reduced to 0/5 during pacing at 200 beats min(-1). Thus, drug-induced proarrhythmia was bradycardia-dependent. 5. Drug-induced prolongation of the interval between the peak and end of the T-wave (QTa-e) was reverse rate-dependent and was associated with the occurrence of torsades de pointes (r = 0.91, P < 0.01). 6. The results suggest that tedisamil, like dofetilide, presents a risk for development of torsades de pointes.
Asunto(s)
Antiarrítmicos/farmacología , Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Ciclopropanos/farmacología , Fenetilaminas/farmacología , Sulfonamidas/farmacología , Torsades de Pointes/fisiopatología , Animales , Relación Dosis-Respuesta a Droga , Electrocardiografía , Corazón/efectos de los fármacos , Corazón/fisiopatología , Técnicas In Vitro , Masculino , Potasio/sangre , Potasio/farmacología , ConejosRESUMEN
Thrombostatins are a group of compounds based upon a breakdown product of bradykinin, RPPGF. They inhibit alpha-thrombin-induced platelet activation by binding to protease activated receptor 1 and, at a lower affinity, by interacting with thrombin's active site. After a single intravenous infusion of MAP4-RPPGF (11.58 mg/kg), its t1/2alpha was 4.5 min with a clearance of 2.0 ml/min. MAP4-RPPGF administration had a sustained antiplatelet effect, preventing gamma-thrombin-induced (12.5 nM) platelet activation for 4 h. Its antiplatelet effect summated with that of aspirin and/or clopidogrel. MAP4-RPPGF was compared with aspirin and clopidogrel in the Folts model of coronary artery thrombosis. Dogs were randomized to 3 treatment groups: aspirin 1.14 mg/kg i.v., clopidogrel 0.5 mg/kg i.v., or MAP4-RPPGF 0.77 mg/kg i.v. Cyclic flow variations (CFV) were recorded in 5 untreated dogs hourly for 3 successive hours and for 1 h before (all groups >11 CFV/h), and for 2 h after drug infusion in each of the 3 treatment groups. After 1 h drug treatment, all groups of animals had <6 CFV/h; after 2 h treatment, all had <1 CFV/h. All agents significantly reduced CFV from control at each hour, but none was significantly better than any other. Thrombostatin was as effective as aspirin or clopidogrel in inhibiting coronary artery thrombosis in this canine model.
Asunto(s)
Bradiquinina/farmacocinética , Trombosis Coronaria/prevención & control , Fragmentos de Péptidos/farmacocinética , Flujo Sanguíneo Regional/efectos de los fármacos , Animales , Aspirina/administración & dosificación , Aspirina/farmacología , Pruebas de Coagulación Sanguínea , Bradiquinina/administración & dosificación , Bradiquinina/análogos & derivados , Bradiquinina/farmacología , Clopidogrel , Estenosis Coronaria , Trombosis Coronaria/tratamiento farmacológico , Modelos Animales de Enfermedad , Perros , Evaluación de Medicamentos , Tasa de Depuración Metabólica , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/farmacología , Pruebas de Función Plaquetaria , Equivalencia Terapéutica , Ticlopidina/administración & dosificación , Ticlopidina/análogos & derivados , Ticlopidina/farmacología , Factores de TiempoRESUMEN
Under normal conditions, the complement system functions to eradicate microbes and other membrane bound pathogens. In other situations, complement activation comprises a pivotal mechanism for mediating tissue demolition in inflammatory disorders, including ischaemia/reperfusion injury. Complement-mediated tissue damage has long been recognised as a significant contributor to myocardial reperfusion injury. However, clinical use of complement inhibitors to reduce the extent of irreversible tissue injury related to reperfusion, remains in the early stages of development. Activation of the complement system generates anaphylatoxins, opsonins and the lytic moiety known as the membrane attack complex (MAC). In addition, fragments of the complement cascade proteins (e.g., C3a and C5a) secondarily initiate processes deleterious to myocytes by recruiting and stimulating inflammatory cells, such as neutrophils and macrophages, within the area of reperfusion. Damaged tissue itself, is capable of upregulating the genes that encode the formation of complement proteins leading to assembly of the MAC, which in turn further advances tissue injury. All of these factors contribute to the development of myocardial infarction subsequent to ischaemia and reperfusion. This paper provides an overview of how the complement system operates and examines the various inhibitors, both endogenous and exogenous, that regulate the complement cascade. Activation and inhibition of the complement system will be discussed primarily in the context of myocardial ischaemia and reperfusion injury.
Asunto(s)
Proteínas Inactivadoras de Complemento/uso terapéutico , Isquemia Miocárdica/tratamiento farmacológico , Animales , Proteínas del Sistema Complemento/fisiología , Humanos , Isquemia Miocárdica/fisiopatología , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Daño por Reperfusión Miocárdica/fisiopatología , Proteínas Recombinantes/uso terapéuticoRESUMEN
P2Y1, P2X1, and P2T receptors mediate ADP-induced platelet aggregation. The antithrombotic effects of AR-C69931MX (N6-[2-methylthio)ethyl]-2-[3,3,3-trifluoropropylthio]-5'-adenylic acid, monoanhydride with dichloromethylenebiphosphonic acid), a selective P2T platelet receptor antagonist, was assessed in a canine model of arterial thrombosis. Placebo or AR-C69931MX (4.0 microg/kg/min for 6 h) pretreatment was administered as an intravenous infusion beginning 15 min before inducing vessel wall injury. A 300-microA anodal current was applied to the intima of the carotid artery for 180 min or discontinued 30 min after cessation of blood flow due to thrombus formation. Each of five control animals developed occlusive thrombi within 3 h after induction of vessel wall injury. In contrast, carotid artery blood flow in five of six AR-C69931MX-treated animals was maintained for the duration of the protocol. Ex vivo platelet aggregation in response to adenosine diphosphate was inhibited at the first measurement time point of 75 min after the start of drug infusion and remained inhibited during drug administration. Bleeding time values were increased in the drug-treated group. Values for both the ex vivo platelet aggregation and the bleeding times returned to control values shortly after discontinuation of AR-C69931MX. The results indicate that AR-C69931MX antagonizes the ex vivo and in vivo aggregatory actions of ADP, and displays a rapid onset and offset of action with the ability to prevent occlusive arterial thrombus formation. AR-C69931MX may be suitable for the management of patients who require short-term modulation of platelet function.
Asunto(s)
Adenosina Monofosfato/análogos & derivados , Adenosina Monofosfato/uso terapéutico , Trombosis de las Arterias Carótidas/prevención & control , Proteínas de la Membrana , Inhibidores de Agregación Plaquetaria/uso terapéutico , Antagonistas del Receptor Purinérgico P2 , Adenosina Difosfato/antagonistas & inhibidores , Adenosina Difosfato/toxicidad , Animales , Arteriopatías Oclusivas/etiología , Arteriopatías Oclusivas/prevención & control , Tiempo de Sangría , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Plaquetas/efectos de los fármacos , Arterias Carótidas/efectos de los fármacos , Trombosis de las Arterias Carótidas/etiología , Modelos Animales de Enfermedad , Perros , Femenino , Hemodinámica/efectos de los fármacos , Inyecciones Intravenosas , Masculino , Agregación Plaquetaria/efectos de los fármacos , Receptores Purinérgicos P2Y12 , Túnica Íntima/lesionesRESUMEN
This investigation examined the effect of preconditioning in an in vivo model of ischemia-reperfusion injury. Anesthetized New Zealand White rabbits underwent 30 min of regional myocardial ischemia followed by 2 h of reperfusion. Hearts preconditioned with two cycles of 5 min ischemia-10 min reperfusion (IPC) or with the ATP-sensitive K (K(ATP)) channel opener, diazoxide (10 mg/kg), exhibited significantly (P < 0.05) smaller infarcts compared with control. These treatments also significantly (P < 0.001 to P < 0.05) reduced C1q, C1r, C3, C8, and C9 mRNA in the areas at risk (AAR). The K(ATP) channel blocker 5-hydroxydecanoate (5-HD; 10 mg/kg) attenuated infarct size reduction elicited by IPC and diazoxide treatment. 5-HD partially reversed the decrease in complement expression caused by IPC but not diazoxide. There were no significant differences in complement gene expression in the nonrisk regions and livers of all groups. Western blot analysis revealed that IPC also reduced membrane attack complex expression in the AAR. The data demonstrate that preconditioning significantly decreases reperfusion-induced myocardial complement expression in vivo.
Asunto(s)
Proteínas del Sistema Complemento/genética , Precondicionamiento Isquémico Miocárdico , Daño por Reperfusión/genética , Animales , Antiarrítmicos/farmacología , Western Blotting , Proteínas del Sistema Complemento/metabolismo , Ácidos Decanoicos/farmacología , Diazóxido/farmacología , Expresión Génica/efectos de los fármacos , Corazón/efectos de los fármacos , Hemodinámica , Hidroxiácidos/farmacología , Hígado/metabolismo , Masculino , Miocardio/metabolismo , ARN Mensajero/metabolismo , Conejos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Vasodilatadores/farmacologíaRESUMEN
Sublytic complement attack can elicit protective cellular responses without precipitating cell death. Our investigation examined the effects of non-lethal complement activation in isolated hearts. New Zealand white rabbit hearts were subjected to 30 min of ischemia followed by 1 h of reperfusion. Prior to ischemia, hearts were perfused for 20 min with 0.5% normal human plasma (NHP). Hearts treated with NHP developed significantly (p<0.05) smaller infarcts compared with controls, expressed as percent of area at risk (AAR) (25.3+/-4.0% vs. 40.9+/-4.3%, respectively). Heat-inactivation, soluble complement receptor 1 (sCR1; 20 nM), and anti-C5a antibody reversed the protective effect of NHP (39.0+/-3.1%, 41.7+/-5.1% and 38.4+/-2.3% AAR, respectively). Hearts treated with 3 nM C5a exhibited infarct sizes similar to those exposed to NHP (27.6+/-5.0% AAR). sCR1 alone did not affect infarct size (37.9+/-4.5% AAR). The results suggest that non-lethal complement activation attenuates reperfusion injury through formation of C5a.
Asunto(s)
Activación de Complemento/inmunología , Complemento C5a/fisiología , Complejo de Ataque a Membrana del Sistema Complemento/fisiología , Infarto del Miocardio/patología , Infarto del Miocardio/prevención & control , Animales , Hemodinámica/inmunología , Hemólisis/inmunología , Humanos , Técnicas In Vitro , Masculino , Infarto del Miocardio/inmunología , Infarto del Miocardio/fisiopatología , Reperfusión Miocárdica , Conejos , Receptores de Complemento 3b/fisiología , SolubilidadRESUMEN
Both free radicals and complement activation can injure tissue. Our study determined whether free radicals alter complement production by the myocardium. Isolated hearts from New Zealand White rabbits were perfused on a Langendorff apparatus and exposed to xanthine (X; 100 microM) plus xanthine oxidase (XO; 8 mU/ml) (X/XO). The free radical-generating system significantly (P < 0.05) increased C1q and also increased C1r, C3, C8, and C9 transcription compared with controls. Immunohistological examination revealed augmented membrane attack complex deposition on X/XO-treated tissue. X/XO-treated hearts also exhibited significant (P < 0.05) increases in coronary perfusion pressure and left ventricular end-diastolic pressure and a decrease in left-ventricular developed pressure. N-(2-mercaptopropionyl)-glycine (3 mM), in conjunction with the superoxide dismutase mimetic SC-52608 (100 microM), significantly (P < 0.05) reduced the upregulation of C1q, C1r, C3, C8, and C9 mRNA expression elicited by X/XO. The antioxidants also ameliorated the deterioration in function caused by X/XO. Local complement activation may represent a mechanism by which free radicals mediate tissue injury.
Asunto(s)
Proteínas del Sistema Complemento/genética , Regulación de la Expresión Génica/efectos de los fármacos , Corazón/efectos de los fármacos , Miocardio/metabolismo , Animales , Complemento C1q/genética , Complemento C3/genética , Complemento C8/genética , Complemento C9/genética , Radicales Libres/farmacología , Técnicas In Vitro , Masculino , Conejos , Receptores de Complemento/genética , Transcripción Genética , Xantina/farmacología , Xantina Oxidasa/farmacologíaRESUMEN
We examined the adjunctive benefit of recombinant nematode anticoagulant peptide (rNAP5), a factor Xa inhibitor, in a canine model of recombinant (rt)-PA-induced thrombolysis. In anesthetized dogs, a stable occlusive thrombus was formed by electrolytic injury of the vessel wall, after which the animals were administered rt-PA (1.44 mg/kg, i.v.) and rNAP5 (0.1 mg/kg, s.c.: n=13), or rt-PA plus vehicle (1-2 ml, s.c.; n=13). Hemodynamic and coagulation parameters were monitored for 360 minutes. Single subcutaneous administration of rNAP5 resulted in a prolonged and sustained increase in the activated partial thromboplastin time (>100-fold), whereas prothrombin time was unchanged. The template bleeding time was not altered significantly throughout the protocol (maximum 1.4-fold). The incidence of reperfusion was similar in the two groups with a trend toward faster reperfusion in the rNAP5 group (34+/-4 minutes) compared to the vehicle group (63+/-15 minutes; p=0.07). After reperfusion, 80% of the vessels in the vehicle group reoccluded, whereas only 14% of vessels reoccluded in the rNAP5-treated group. Times to reocclusion were 65+/-21 minutes and 221+/-28 minutes, respectively (p<0.05). Single subcutaneous administration of rNAP5 sustained the coronary artery blood flow after reperfusion, such that at the end of protocol the flow was 47% of the preocclusion value as compared to the vehicle group in which the flow was 11% (p<0.05). Cyclic flow reductions were most prominent during rt-PA-induced reperfusion and were similar in both groups. The results indicate that a single subcutaneous administration of rNAP5 provides a sustained antithrombotic effect in maintaining the coronary artery patency during rt-PA-induced thrombolysis.
Asunto(s)
Trombosis Coronaria/tratamiento farmacológico , Proteínas del Helminto/uso terapéutico , Terapia Trombolítica , Adyuvantes Farmacéuticos , Animales , Antitrombina III/uso terapéutico , Pruebas de Coagulación Sanguínea , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Trombosis Coronaria/complicaciones , Modelos Animales de Enfermedad , Perros , Fibrinolíticos/sangre , Fibrinolíticos/farmacocinética , Fibrinolíticos/uso terapéutico , Proteínas del Helminto/sangre , Proteínas del Helminto/farmacocinética , Infarto del Miocardio/etiología , Proteínas Recombinantes/sangre , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/uso terapéutico , Reperfusión/métodos , Activador de Tejido Plasminógeno/uso terapéutico , Grado de Desobstrucción Vascular/efectos de los fármacosRESUMEN
Several preclinical studies have found a poor correlation between the ex vivo platelet inhibitory potency and the in vivo antithrombotic efficacy of GPIIb/IIIa receptor antagonists. The present study was designed to examine the differential in vitro potencies of c7E3, MK-383, DMP-728, and SM-20302 in inhibiting ex vivo platelet aggregation under normocalcemic and hypocalcemic conditions. Human blood was collected in either trisodium citrate (0. 37%) or PPACK (20 microg/mL). Platelet aggregation assays were performed in platelet-rich plasma from citrate-anticoagulated blood (cPRP) and PPACK-anticoagulated blood (pPRP) using ADP (20 microM) and TRAP (10 microM) as agonists in the presence of c7E3, MK-383, DMP-728, or SM-20302. The concentration of ionized calcium in cPRP was 16-19 times lower than that in pPRP. The IC(50) of c7E3 for inhibiting ADP-induced platelet aggregation in cPRP (2.76 +/- 0.11 microg/mL) was 1.6 times lower than that in pPRP (4.46 +/- 0.48 microg/mL; P < 0.05). Similarly, the IC(50) for c7E3 for inhibiting TRAP-induced platelet aggregation in cPRP (4.52 +/- 0.34 microg/mL) was 1.7 times lower than that in pPRP (7.69 +/- 0.43 microg/mL; P < 0.05). MK-383, DMP-728, and SM-20302 also demonstrated 1.96-, 1.15-, and 1.43-fold lower IC(50) values, respectively, in cPRP as compared with pPRP. Chelation of ionized calcium in pPRP led to a progressive increase in platelet inhibition by all the antagonists. These results suggest that the observed in vitro inhibitory potency of a GPIIb/IIIa receptor antagonist is markedly enhanced when trisodium citrate is used as an anticoagulant to collect blood for ex vivo assay. These findings indicate that dosing regimens for GPIIb/IIIa receptor antagonists based on the platelet inhibition profile in citrate may provide misleading information with respect to their true in vivo antithrombotic efficacy.
Asunto(s)
Calcio/farmacología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/antagonistas & inhibidores , Adenosina Difosfato/farmacología , Clorometilcetonas de Aminoácidos/farmacología , Anticoagulantes/farmacología , Antitrombinas/farmacología , Calcio/sangre , Quelantes/farmacología , Citratos/farmacología , Humanos , Agregación Plaquetaria/efectos de los fármacos , Inhibidores de Agregación Plaquetaria/farmacología , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/efectos de los fármacos , Citrato de SodioRESUMEN
The exact mechanism of the cardiotoxic actions of cocaine remains unclear. The finding that the heart may be a source of injurious complement components led us to investigate whether cocaine promotes myocardial expression of complement. Rabbit isolated hearts were perfused for 70 min with either cocaine hydrochloride (1 or 10 microM), the synthetic isomer (+)-cocaine (10 microM), or procaine hydrochloride (10 or 30 microM). Compared with controls perfused with drug-free buffer, both cocaine and procaine significantly (P <. 05) increased myocardial C1q, C1r, C8, and C9 mRNA expression, whereas 10 microM (+)-cocaine had no effect on complement mRNA expression. Cocaine also significantly increased (P <.05) C3 mRNA transcription. In addition, in vivo administration of cocaine (1 mg/kg) for three consecutive days significantly increased myocardial complement mRNA expression. Cocaine and procaine also increased membrane attack complex (MAC) formation in the myocardium. The antioxidant 2-N-mercaptopropionyl glycine, attenuated the increases in complement mRNA expression induced by 1 microM cocaine and 10 microM procaine. In vivo heparin administration (300 U/kg i.v.), 2 h before removal of the heart and exposure to 1 microM cocaine, did not inhibit C1q, C1r, C3, and C8 mRNA transcription, but decreased MAC expression. It was determined previously that heparin reduces myocardial ischemia/reperfusion injury. Our results suggest that cocaine may cause myocardial injury by up-regulating local complement expression, possibly via the production of reactive oxygen species. Furthermore, the glycosaminoglycan heparin may modulate the cytotoxic effects of cocaine by impeding formation of the MAC.
Asunto(s)
Cocaína/farmacología , Proteínas del Sistema Complemento/metabolismo , Corazón/efectos de los fármacos , Animales , Western Blotting , Complejo de Ataque a Membrana del Sistema Complemento/metabolismo , Proteínas del Sistema Complemento/genética , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Hemodinámica/efectos de los fármacos , Heparina/farmacología , Técnicas In Vitro , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Perfusión , Procaína/farmacología , ARN Mensajero/metabolismo , Conejos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo , Tiopronina/farmacología , Regulación hacia Arriba/efectos de los fármacosRESUMEN
Reperfusion of the ischemic myocardium results in irreversible tissue injury and cell necrosis, leading to decreased cardiac performance. While early reperfusion of the heart is essential in preventing further tissue damage due to ischemia, reintroduction of blood flow can expedite the death of vulnerable, but still viable, myocardial tissue, by initiating a series of events involving both intracellular and extracellular mechanisms. In the last decade, extensive efforts have focused on the role of cytotoxic reactive oxygen species, complement activation, neutrophil adhesion, and the interactions between complement and neutrophils during myocardial reperfusion injury. Without reperfusion, myocardial cell death evolves slowly over the course of hours. In contrast, reperfusion after an ischemic insult of sufficient duration initiates an inflammatory response, beginning with complement activation, followed by the recruitment and accumulation of neutrophils into the reperfused myocardium. Modulation of the inflammatory response, therefore, constitutes a potential pharmacological target to protect the heart from reperfusion injury. Recognition of the initiating factor(s) involved in myocardial reperfusion injury should aid in development of pharmacological interventions to selectively or collectively attenuate the sequence of events that mediate extension of tissue injury beyond that caused by the ischemic insult.
Asunto(s)
Daño por Reperfusión Miocárdica/fisiopatología , Animales , Supervivencia Celular/fisiología , Activación de Complemento/fisiología , Humanos , Contracción Miocárdica/fisiología , Activación Neutrófila/fisiología , Especies Reactivas de Oxígeno/metabolismo , Síndrome de Respuesta Inflamatoria Sistémica/fisiopatologíaRESUMEN
Both preconditioning and inhibition of complement activation have been shown to ameliorate myocardial ischemia-reperfusion injury. The recent demonstration that myocardial tissue expresses complement components led us to investigate whether preconditioning affects complement expression in the isolated heart. Hearts from New Zealand White rabbits were exposed to either two rounds of 5 min global ischemia followed by 10 min reperfusion (ischemic preconditioning) or 10 microM of the ATP-dependent K+ (KATP) channel opener pinacidil for 30 min (chemical preconditioning) before induction of 30 min global ischemia followed by 60 min of reperfusion. Both ischemic and chemical preconditioning significantly (P < 0.05) reduced myocardial C1q, C1r, C3, C8, and C9 mRNA levels. Western blot and immunohistochemistry demonstrated a similar reduction in C3 and membrane attack complex protein expression. The K(ATP) channel blocker glyburide (10 microM) reversed the depression of C1q, C1r, C3, C8, and C9 mRNA expression observed in the pinacidil-treated hearts. The results suggest that reduction of local tissue complement production may be one means by which preconditioning protects the ischemic myocardium.
Asunto(s)
Proteínas del Sistema Complemento/genética , Regulación de la Expresión Génica , Precondicionamiento Isquémico , Miocardio/metabolismo , Canales de Potasio/fisiología , Transcripción Genética , Animales , Cartilla de ADN , Regulación de la Expresión Génica/efectos de los fármacos , Gliburida/farmacología , Técnicas In Vitro , Masculino , Isquemia Miocárdica , Reperfusión Miocárdica , Pinacidilo/farmacología , Bloqueadores de los Canales de Potasio , ARN Mensajero/genética , Conejos , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transcripción Genética/efectos de los fármacosRESUMEN
Thrombostatin (RPPGF), an angiotensin converting enzyme metabolite of bradykinin, is an inhibitor of alpha-thrombin's ability to activate platelets. We examined the in vivo pharmacokinetics and pharmacodynamics of thrombostatin in rabbits and its ability to inhibit coronary thrombosis induced by electrolytic injury in dogs. Plasma half-life of thrombostatin had a t1/2alpha of 2.6 min and a t1/2beta of 24 min in rabbits. Ligating the renal arteries did not prolong clearance (t1/2alpha = 2.4 min; t1/2beta = 12 min). Thrombostatin produced a prolonged in vivo antiplatelet effect. At 30 min after a single intravenous administration in rabbits, thrombostatin's plasma concentration was <8.7 microM (5 microg/ml). However, ex vivo 20 and 40 nM gamma-thrombin-induced platelet aggregation of these rabbits' platelets was inhibited 40% for 2.75 and 1 h, respectively. In vitro, flow cytometry studies revealed that thrombostatin specifically bound to human platelets and washed human platelets treated with thrombostatin were less responsive to gamma-thrombin than control platelets. Using electrolytic injury to induce coronary artery thrombosis, dogs treated with thrombostatin, aspirin, or combined thrombostatin and aspirin occluded in 62+/-25 (mean +/- SD), 62+/-36, or 89+/-32 min versus untreated animals which occluded at 39+/-27 min, (p<0.01, p<0.01 and p<0.001, respectively). These studies show that thrombostatin binds to platelets and can delay coronary occlusion in vivo.